{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:15:28Z","timestamp":1792278928146,"version":"4.4.0"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.1677","type":"journal-article","created":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T23:00:36Z","timestamp":1394838036000},"page":"571-575","source":"Crossref","is-referenced-by-count":32,"title":["Eradication of &lt;i&gt;H. pylori&lt;\/i&gt; Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin"],"prefix":"10.2169","volume":"53","author":[{"given":"Takahisa","family":"Furuta","sequence":"first","affiliation":[{"name":"Center for Clinical Research, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsushige","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Uotani","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Sahara","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Kagami","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yamada","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Umemura","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Hamamatsu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Malfertheiner P. Guidelines for the diagnosis and treatment of <i>H. pylori<\/i> infection. MMW Fortschr Med 145: 42-45, 2003."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Muranaka M, Kabe J, Umezono K, et al. Incidence of drug hypersensitivity. Jpn J Allergol 13: 431-434, 1964 (in Japanese, Abstract in English).","DOI":"10.1295\/kobunshi.13.431"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Muranaka M, Okumura H, Takeda K, et al. Population studies on drug hypersensitivities. Acta Allergol 28: 50-61, 1973.","DOI":"10.1111\/j.1398-9995.1973.tb02565.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Harris AW, Pryce DI, Gabe SM, et al. Lansoprazole, clarithromycin and metronidazole for seven days in <i>Helicobacter pylori<\/i> infection. Aliment Pharmacol Ther 10: 1005-1008, 1996.","DOI":"10.1046\/j.1365-2036.1996.100272000.x"},{"key":"5","unstructured":"5. Dore MP, Leandro G, Realdi G, et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of <i>Helicobacter pylori<\/i> therapy: a meta-analytical approach. Dig Dis Sci 45: 68-76, 2000."},{"key":"6","unstructured":"6. Watanabe K, Tanaka A, Imase K, et al. Amoxicillin resistance in <i>Helicobacter pylori<\/i>: studies from Tokyo, Japan from 1985 to 2003. Helicobacter 10: 4-11, 2005."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Murakami K, Sato R, Okimoto T, et al. Effectiveness of minocycline-based triple therapy for eradication of <i>Helicobacter pylori<\/i> infection. J Gastroenterol Hepatol 21: 262-267, 2006.","DOI":"10.1111\/j.1440-1746.2006.04183.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Murakami K, Okimoto T, Kodama M, et al. Sitafloxacin activity against <i>Helicobacter pylori<\/i> isolates, including those with gyrA mutations. Antimicrob Agents Chemother 53: 3097-3099, 2009.","DOI":"10.1128\/AAC.01552-08"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Karczewska E, Klesiewicz K, Skiba I, et al. Variability in prevalence of <i>Helicobacter pylori<\/i> strains resistant to clarithromycin and levofloxacin in southern Poland. Gastroenterol Res Pract 2012: 418010, 2012.","DOI":"10.1155\/2012\/418010"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bogaerts P, Berhin C, Nizet H, et al. Prevalence and mechanisms of resistance to fluoroquinolones in <i>Helicobacter pylori<\/i> strains from patients living in Belgium. Helicobacter 11: 441-445, 2006.","DOI":"10.1111\/j.1523-5378.2006.00436.x"},{"key":"11","unstructured":"11. Furuta T, Soya Y, Sugimoto M, et al. Rapid automated genotyping of CYP2C19 and <i>Helicobacter pylori<\/i> 23S rRNA gene in gastric juice. Gastroenterol Hepatol Res 2: 508-512, 2013."},{"key":"12","unstructured":"12. Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for <i>Helicobacter pylori<\/i> re-treatment: role of bacterial resistance. Dig Liver Dis 39: 1001-1005, 2007."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yamade M, Sugimoto M, Uotani T, et al. Resistance of <i>Helicobacter pylori<\/i> to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol 26: 1457-1461, 2011.","DOI":"10.1111\/j.1440-1746.2011.06815.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hirata Y, Ohmae T, Yanai A, et al. Sitafloxacin resistance in <i>Helicobacter pylori<\/i> isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents 39: 352-355, 2012.","DOI":"10.1016\/j.ijantimicag.2011.12.002"},{"key":"15","unstructured":"15. Furuta T, Sugimoto M, Uotani T, et al. Present status and future prospects of third line rescue regimens for <i>H. pylori<\/i> infection. Nihon Rinsho 71: 1404-1412, 2013 (in Japanese)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gisbert JP, Perez-Aisa A, Castro-Fernandez M, et al. <i>Helicobacter pylori<\/i> first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis 42: 287-290, 2010.","DOI":"10.1016\/j.dld.2009.06.007"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gisbert JP, Gisbert JL, Marcos S, et al. <i>Helicobacter pylori<\/i> first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 22: 1041-1046, 2005.","DOI":"10.1111\/j.1365-2036.2005.02687.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 1: 121-128, 2002.","DOI":"10.1517\/14740338.1.2.121"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, et al. High eradication rates of <i>Helicobacter pylori<\/i> infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci 50: 634-639, 2005.","DOI":"10.1007\/s10620-005-2549-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Furuta T, Sugimoto M, Shirai N, et al. CYP2C19 pharmacogenomics associated with therapy of <i>Helicobacter pylori<\/i> infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 8: 1199-1210, 2007.","DOI":"10.2217\/14622416.8.9.1199"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/6\/53_53.1677\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:51:10Z","timestamp":1621446670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/6\/53_53.1677\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.1677","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}